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in the FACT-P total score of -9.68 (95% CI: [-16.10; -3.27]); pathological bone fractures 
and radiation or surgery to bone determined changes in FACT-P total score of -7.61 
(95% CI: [-16.79; 1.56]) and -6.68 (95% CI: [-10.25; -3.11]), respectively. The standardized 
effect size was moderate (any SRE: -0.32; spinal cord compression: -0.49; pathological 
bone fracture: -0.35; radiation or surgery to bone: -0.30). ConClusions: Consistent 
with previous analyses in metastatic prostate cancer [Weinfurt K.P., et al. Annals of 
Oncology 2005;16: 579–584], our findings demonstrate that SREs lead to significant 
functional declines in patients’ daily lives. Therefore, any therapy reducing or delaying 
the occurrence of SREs should also reduce the effects of SREs on HRQOL.
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CaN admiNistrative data PrediCt ChemotheraPy adverse eveNts?
Pearce A.M., Haas M., Viney R.
University of Technology, Sydney, Ultimo, Australia
objeCtives: The rates of adverse events (AEs) are an important component of 
chemotherapy cost effectiveness. However, AE rates in clinical practice are diffi-
cult to obtain. This study aimed to determine whether Australian administrative 
data could identify the incidence of selected chemotherapy AEs. Methods: The 
Elements of Care study (EoC) was a prospective cohort of individuals in New South 
Wales undergoing chemotherapy for breast, colorectal or lung cancer. Primary 
data, including AEs experienced, was collected through questionnaires and medi-
cal record review. Linked administrative data of prescriptions and medical services 
for each participant were available from the Pharmaceutical Benefits Scheme (PBS) 
and Medicare Benefits Schedule (MBS). This data was used to identify if an indi-
vidual was treated for one of the selected AEs (diarrhoea, vomiting, anaemia and 
neutropenia) in the three days after a chemotherapy dose. These proxy-identified AE 
rates were compared with the self-reported AE rates using 2x2 contingency tables, 
with significance of any differences calculated using odds ratios and chi-square 
statistics. Results: There were 482 individuals in EoC. The proxy identified much 
lower rates of AEs than were self-reported, capturing 30% of self-reported cases 
of nausea and vomiting, 1.3% of self-reported diarrhoea, and less than 1% of self-
reported anaemia and neutropenia. Additional analyses did not identify a pattern 
in the grade of AEs or type of treatment received that the proxy was more likely 
to identify. ConClusions: Overall there was poor concordance between the two 
measures of AE rates. This may be due to low treatment rates for AEs, poor capturing 
of AE treatments by the proxy, or over-reporting of adverse event by participants. 
Regardless, it would appear that administrative data such as the MBS and PBS are 
not suitable for estimating the incidence of AEs in clinical practice, and bottom up 
data collection techniques such as EoC are essential.
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objeCtives: To evaluate the burden of skin cancer among U.S. veteran 
patients. Methods: Patients diagnosed with skin cancer were identified (International 
Classification of Disease 9th Revision Clinical Modification [ICD-9-CM] diagnosis code 
232.xx) using the Veterans Health Administration (VHA) Medical SAS datasets from 
October 1, 2009 to September 30, 2011. The first diagnosis date was defined as the index 
date. A comparison group of patients without skin cancer of the same age, region, gen-
der and index year were identified and matched on baseline Charlson Comorbidity 
Index with a randomly chosen index date to minimize selection bias. Patients in both 
groups were required to be at least 18 years old and have 1 year continuous health plan 
enrollment pre- and post-index date. Follow-up health care costs and utilizations were 
compared between the two groups after using 1:1 propensity score matching adjust-
ing baseline characteristics. Results: A total of 12,504 patients were identified for the 
skin cancer and comparison cohorts. After 1:1 propensity score matching, each group 
included 4,400 patients with well-balanced baseline demographic and clinical charac-
teristics. Patients diagnosed with skin cancer had higher percentages of inpatient (5.75% 
vs. 2.64%, p< 0.01), emergency room (11.89% vs. 6.50%, p< 0.01), physician office (99.95% 
vs. 66.70%, p< 0.01), outpatient (99.95% vs. 67.41%, p< 0.01), and pharmacy visits (91.89% 
vs. 71.30%, p< 0.01). Patients in the skin cancer cohort also incurred higher expenditures 
in inpatient ($1,494 vs. $555, p< 0.01), emergency room ($108 vs. $60, p< 0.01), physician 
office ($4,486 vs. $1,480, p< 0.01), outpatient ($4,780 vs. $1,639) and pharmacy visits ($707 
vs. $429, p< 0.01) than patients in the comparison group. ConClusions: Study results 
suggest that cancer patients diagnosed with skin cancer incurred significantly higher 
costs and health care resources compared to patients without.
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objeCtives: To examine the economic burden and health care utilizations of 
colorectal cancer patients in the U.S. veteran population. Methods: A retrospec-
tive database analysis was performed using the Veterans Health Administration 
Medical SAS datasets (01OCT2008-30SEP2012). Patients (≥ 18 years of age) diagnosed 
with colorectal cancer (International Classification of Disease 9th Revision Clinical 
Modification ICD-9-CM codes 153.xx, 154.xx) were identified. The first diagnosis 
date was designated as the index date. A comparator group was created by cat-
egorizing patients without colorectal cancer but of the same age, region, gender 
and index year, and matching them by baseline Charlson Comorbidity Index. The 
index date for the comparison group was selected randomly to minimize selection 
bias. Continuous medical and pharmacy benefits for 1 year pre- and 1 year post-
index date were required. One-to-one propensity score matching (PSM) was used to 
compare the health care costs and utilizations during the follow-up period between 
researCh Poster PreseNtatioNs – sessioN ii 
disease-sPeCifiC studies 
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objeCtives: Notable side effects of abiraterone for advanced prostate cancer are 
oedema, hypertension, and hypokalemia, constituting a mineralocorticoid excess 
syndrome (MES). Although abiraterone is co-administered with prednisone to 
minimise MES symptoms, they remain a burden requiring concomitant therapies 
to manage each toxicity and/or treatment with costly mineralocorticoid receptor 
antagonists. A literature review was conducted to assess the impact of MES symp-
toms on health-related quality of life (HRQoL) and health care costs in patients 
across a number of disease areas. Methods: Outside prostate cancer, MES is a 
broad syndrome which is best characterised as bilateral primary aldosteronism 
(PA). Electronic databases were searched for data on the economic and humanistic 
burden of MES (or its symptoms in combination) and/or PA. Results: Even though 
no studies were identified in a specific prostate cancer population, nine studies 
found humanistic burden and three of the economic burden related to MES (PA) in 
the literature. Patients with MES (PA) had significantly impaired HRQoL (measured 
by SF36 and SF12) compared with the general population, especially on physical 
domains, general health perceptions, and vitality. Patients also exhibited greater 
levels of anxiety, depression and somatization. Use of mineralocorticoid receptor 
antagonists was associated with reduced HRQoL. Despite sparse direct economic 
data on MES, hypertension and oedema were associated with increased health 
care resources and costs. Chronic oedema was additionally associated with hospi-
talisation and lost productivity. ConClusions: MES symptoms can significantly 
impair HRQoL and may increase resource use. The impact of these symptoms in an 
advanced prostate cancer population is likely to be exacerbated, as many of these 
elderly patients already have serious co-morbidities. Further research is required 
to determine the incidence and severity of MES in patients receiving abiraterone in 
actual clinical practice and the impact these symptoms have on health care resource 
use and the well-being of patients with prostate cancer.
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BisPhosPhoNates-assoCiated osteoNeCrosis of Jaw iN CaNCer 
PatieNts: a meta-aNalysis
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objeCtives: This meta-analysis aims to assess the incidence of osteonecrosis of 
the jaw(ONJ)associated with bisphosphonates in cancer patients. Methods: The 
published literature was systematically searched and reviewed using MEDLINE and 
the Cochrane Central Register of Controlled Trials on 30 April 2013. Any randomized 
controlled trial assessing the role of bisphosphonates in cancer patients and clearly 
mentioned the event of ONJ were eligible for inclusion. Studies that included spe-
cific risk estimates were pooled using a random-effects model. The quality of these 
studies were assessed with RevMan statistical software (version 5.0). Results: 
Eight of 21 randomized controlled clinical trials were included. Thirteen studies 
were excluded due to no cases of osteonecrosis of jaw were reported. A total of 
13,399 patients were collected in eight studies, 6686 patients were assigned to bis-
phosphonates group and 6713 were assigned to control group. Twenty-eight cases 
(28/6686,0.42%) of ONJ were reported in bisphosphonates group. No patient was 
reported in control group. Risk ratio was used to estimate the risk of osteonecrosis 
of the jaw associated with bisphosphonate. Pooled results showed very lower risk 
of ONJ associated with bisphosphonates 5.61 (95% CI: 1.90, 16.52). No heterogeneity 
was found in our study. ConClusions: Although the risk ratio of ONJ associated 
with the use of bisphosphonates is low in our study, we still need to suggest physi-
cians to make a particular concern on using bisphosphonates in cancer patients. We 
suggest that a large and well design of risk of ONJ as primary endpoint, prospective 
multi-center studies should be conducted in the future.
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skeletal-related eveNts have a sigNifiCaNt imPaCt oN health-
related Quality of life iN meN with metastatiC CastratioN 
resistaNt Prostate CaNCer (mCrPC) followiNg doCetaxel theraPy 
failure
Ivanescu C.1, Phung D.2, Holmstrom S.2
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objeCtives: Patients with mCRPC are at risk of experiencing skeletal-related events 
(SREs), defined as pathologic fracture, spinal cord compression, and the need for radio-
therapy or surgery to bone. We examined the immediate impact of an SRE on patients’ 
HRQoL. Methods: Data were obtained from the AFFIRM study, a phase 3 trial of 
enzalutamide vs. placebo in patients with mCRPC. Only patients experiencing any type 
of SRE were included in the analysis (n= 284). For patients with multiple SREs, only the 
first event was used. HRQoL was assessed at baseline and at fixed intervals throughout 
the study until treatment discontinuation using the FACT-P (Functional Assessment of 
Cancer Therapy–Prostate) instrument. We used linear mixed-effects models to model 
each patient’s longitudinal trajectory of FACT-P outcomes before the first SRE and to 
estimate how far the post-SRE value of HRQoL deviated from that trajectory. Results: 
SREs were associated with a deterioration of HRQoL with an adjusted mean change of 
-6.93 (95% CI: [-9.92; -3.95]) of the FACT-P total score for any SRE. The largest impact was 
observed in subjects with spinal cord compression, which induced a mean decrease 
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objeCtives: Women of childbearing age with a diagnosis of breast cancer often 
want to conceive a child after treatment. Some reports found that pregnancy does 
not increase the risk of cancer recurrence after successful treatment. These reports 
and positive changes in the survival rates of breast cancer patients can impact the 
decisions of patients and physicians. The goal of this study was to estimate the 
number of women who survived breast cancer and subsequently became preg-
nant and to determine the time between the cancer diagnosis and pregnancy in 
the time periods between 2000-2002 and 2010-2012, respectively. Methods: This 
retrospective study analysed longitudinal routine care data collected by gynaecolo-
gists in Germany (IMS® Disease Analyzer). Data from women aged 20-45 with a 
pregnancy within 10 years after the first breast cancer diagnosis from 102 gynae-
cological practices in Germany (Disease Analyzer database; 01/1992 to 12/2012) 
were analysed. Results: In the time period 2000-2002, 65 (projected to national 
level: 4615) women became pregnant after a breast cancer diagnosis; this number 
increased to 114 (projected to national level: 8094) between 2010-2012. The mean 
age did not significantly change between 2000-2002 and 2010-2012 (33.8 (SD: 6.0) 
and 34.2 years (SD: 6.1)). The time between the first breast cancer diagnosis and 
pregnancy identification was 896 days (SD: 690) in 2000-2012 and 552 days (SD: 
696) in 2010-2012 (p< 0.01). ConClusions: This retrospective analysis showed 
that the number of pregnancies following breast cancer diagnosis has signifi-
cantly increased in the last 10 years. More over, the time to pregnancy has become 
significantly shorter. This is indicative of the positive and hopeful developments 
for young women affected by breast cancer. Further studies on this important 
research topic are necessary.
PCN10
evaluatioN of variaBle relevaNCe aNd aCCessiBility to suPPort 
PersoNalized mediCiNe iN Breast CaNCer
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objeCtives: About 1 in 8 U.S. women will develop invasive breast cancer during 
their lifetime. Response to treatment varies among women depending on several 
factors. This work identified and prioritized the essential variables to imple-
ment personalized cancer treatment, and determined the feasibility of obtaining 
these variables from available data sources toward a real time clinical decision 
aid. Methods: A focus group of 10 breast cancer clinicians was conducted to deter-
mine possible variables for inclusion into the clinical dashboard. An electronic 3-cat-
egorical scale (must have, would like to have, unnecessary) survey was conducted 
among a broader group of breast cancer clinicians. Variables were classified by 
category and mention frequency (Mode). The accessibility of these variables from 
two separate cancer care databases was evaluated by data querying, text search and 
electronic chart review and categorized as available, difficult to access, or unavail-
able. Results: Ten clinicians identified 67 possible variables for inclusion into the 
dashboard. According to the broader electronic survey 25 clinicians determined 
39 “must have” variables with 9 patient specific variables (e.g. age at diagnosis, 
comorbidities, hormone replacement use, cancer history); 13 tumor specific vari-
ables (e.g. clinical stage at diagnosis, histologic grade, laterality) and 17 timeline 
related variables (e.g. date and type of surgery, chemo/endocrine/targeted therapies 
received by date, chemotherapy regimen and cycle information, overall survival). 
34 of identified “must have” variables were accessible from at least one of available 
databases. Of the relevant variables five may be difficult to access, including BRCA 
testing and status, performance status, date and site of recurrence, disease free 
survival and treatment delay. ConClusions: Breast cancer clinicians identified 39 
essential variables, the majority of which can be obtained from currently available 
databases and then uploaded into a clinical dashboard to support personalized 
medicine at the point of care for patients with breast cancer.
PCN11
aN iNdireCt treatmeNt ComParisoN of the effiCaCy of everolimus 
(afiNitor®) aNd fulvestraNt for the treatmeNt of hormoNe 
reCePtor Positive (hr+) her2 Negative (her2–) advaNCed or metastatiC 
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objeCtives: To indirectly compare the efficacy (progression free survival (PFS)/
time to progression (TTP) and overall survival (OS) of everolimus plus exemes-
tane (EVE+EXE) with fulvestrant in patients with hormone receptor positive, HER2 
negative advanced or metastatic breast cancer. Methods: A systematic search of 
the Cochrane Library and other resources was undertaken to identify reviews and 
clinical trials reporting interventions for metastatic breast cancer that would allow 
an indirect comparison of fulvestrant and EVE+EXE. A Bayesian fixed effect model 
was used with exemestane adopted as the base treatment for the model because it 
provided the most information in the network. The basic parameters of the model 
are the log hazard ratios with respect to exemestane for PFS/TTP and OS from the 
included studies. In the absence of full networks for TTP/PFS, these outcomes were 
assumed to be the same measure in a disease with short survival times. Results: 
Six trials contributed to a network for PFS/TTP and five to a network for OS. Because 
the comparator treatment was used as the base treatment, a HR > 1 indicates that 
the comparator is less effective than everolimus. For PFS/TTP, EVE+EXE performed 
better than fulvestrant 250mg (HR 2.13 Credible interval (CI):1.72 to 2.63) and 500mg 
(HR 1.69 CI: 1.30 to 2.22). This difference was statistically significant. For OS, EVE+EXE 
performed better than fulvestrant 250mg (HR 1.36 Cl: 0.95 to 1.97) and 500mg (HR 
1.15 Cl: 0.76 to 1.75) but the difference was not statistically significant. A complete 
statistical assessment of heterogeneity for PFS/TTP and OS was not possible because 
of data limitations. ConClusions: EVE+EXE confers better PFS/TTP benefit in HR+ 
HER2-ve metastatic breast cancer when indirectly compared with fulvestrant 250mg 
the colorectal cancer and comparison groups, adjusted for baseline demographic 
and clinical characteristics. Results: A total of 75,208 patients were identified 
for the colorectal cancer and comparison cohorts. After 1:1 PSM, 24,053 patients 
were matched from each group, and the baseline characteristics were proportion-
ate. Patients diagnosed with colorectal cancer had more health care utilization 
including inpatient (20.40% vs. 2.61%, p< 0.01), emergency room (ER) (15.32% vs. 
6.06%, p< 0.01), outpatient (99.60% vs. 64.31%, p< 0.01) and pharmacy visits (88.30% 
vs. 66.20%, p< 0.01). The higher health care utilization resulted in increased health 
care costs, including high inpatient ($9,867 vs. $795, p< 0.01), ER ($158 vs. $61, p< 0.01), 
outpatient ($5,020 vs. $1,585, p< 0.01), pharmacy ($1,345 vs. $523, p< 0.01) and total 
costs ($16,232 vs. $2,903, p< 0.01) for patients diagnosed with colorectal cancer 
compared to patients in the comparison group. ConClusions: Veteran patients 
diagnosed with colorectal cancer incurred significantly higher health care utiliza-
tion and costs over a 1-year period compared to patients without colorectal cancer.
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westerN euroPe: amBitioN study (aNalysis of moleCular Biomarker 
tests iN oNCology)
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objeCtives: The development of targeted therapies has changed the paradigm of 
cancer management necessitating the use of robust biomarkers to identify eligible 
patients. This study aims to evaluate trends in molecular diagnostic test (MDT) uptake 
across various solid tumors. Methods: This study used IMS Oncology Analyzer™, a 
patient database collected through a quarterly physician panel survey. This database 
provides comprehensive insight into cancer care. Selected patients were at advanced/
metastatic stages and diagnosed with breast (BC), stomach (SC), non-small cell lung 
cancer (NSCLC) or colorectal cancer (CRC) and receiving chemotherapy. MDT uptake 
was analyzed from time 0 (year of the European Medicines Agency –EMA– approval 
of the associated targeted therapy) until 2012. The analysis was done on 5 EU coun-
tries (France, Germany, Italy, Spain and UK). Results: Trastuzumab was approved 
in HER2+ BC by the EMA in 2000 and had a line extension in 2004. In metastatic 
BC, the proportion of HER2-tested patients in 2004 was 60% (787/1,320) versus 94% 
(1,351/1,430) in 2012. Following further approval in 2010 for use in HER2+ advanced SC, 
HER2-testing grew from 17% (176/1,015) to 50% (501/993) between 2010 and 2012 in this 
population. In the year that Gefitinib gained EMA approval in EGFR+ NSCLC (2009), 8% 
of advanced NSCLC patients (280/3,465) were EGFR-tested. This proportion increased 
to 56% (2,092/3,708) in 2012. Panitumumab and Cetuximab obtained EMA approval for 
KRAS-wild type CRC in 2007 and 2008 respectively. In 2009, 42% (1,183/2,843) of meta-
static CRC patients were K-RAS-tested and 62% (1,782/2,873) in 2012. ConClusions: 
The use of MDTs has become increasingly important in oncology as more targeted 
therapies are launched. While consistent growth in testing is established, differences 
exist in the delay to achieving routine testing of patients. Further observation of MDT 
usage is required, considering national health guidelines, to better understand move-
ment towards personalized cancer management.
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a lessoN learNt from avastiN®: - BevaCizumaB iNduCed 
hyPerteNsioN as a PrediCtive Biomarker of PatieNt resPoNse iN 
overComiNg regulatory aNd health teChNology assessmeNt (hta) 
hurdles
Fowler R.C., Street-Docherty L.M., Morrison S.
GfK Bridgehead, Melton Mowbray, UK
bACkgRound: The high cost of VEGF-targeted anti-angiogenic therapies within a 
financially strained health-system, makes reimbursement decisions a potentially lim-
iting factor for new compounds. Failure to demonstrate adequate clinical benefit and 
cost-effectiveness in HER-2 negative metastatic breast cancer resulted in significant 
regulatory and health technology assessment (HTA) challenges. There is increasing 
expectation for new drugs to have companion diagnostics that identify likely patient 
responders, with growing support for using biomarkers to inform treatment deci-
sions objeCtives: The purpose of this study was to critically examine published lit-
erature on trials incorporating biomarkers related to VEGF inhibition across different 
cancer indications, to explore their value as predictive, prognostic, pharmacological 
or surrogate response biomarkers Methods: A search with a strict set of inclusion 
criteria was used to review the current literature. Information was gathered for 13 
biomarkers that have been explored for anti-VEGF therapy and a database was com-
piled housing raw experimental data for comparison. Each biomarker was critically 
evaluated and ranked accordingly, to validate their potential as predictive, prognostic, 
pharmacodynamic and surrogate endpoint markers for bevacizumab-based therapies, 
with consideration for likely regulatory, clinical and payer acceptance. Results: A 
total of 222 published studies were incorporated into the analysis. Plasma VEGF-A, 
PlGF and soluble VEGFR-1/VEGFR-2 demonstrated value as pharmacodynamic bio-
markers with limited prognostic value. CECs and CA19-9 showed prognostic and 
predictive value under restricted indications. Blood pressure demonstrated superior-
ity in its ability to predict response to bevacizumab. ConClusions: The evidence 
suggests the incorporation of biomarkers in clinical trial design must be tailored to 
the drug and the cancer indication to which the therapy is applied. The potential for 
blood pressure as a biomarker of response to bevacizumab has been highlighted. 
Bevacizumab-induced hypertension should therefore be considered as a key candi-
date for future biomarker-driven trials, increasing the likelihood of test-treatment 
acceptance by key regulatory and HTA stakeholders.
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